Current Report Filing (8-k)
January 22 2020 - 4:45PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
January 16, 2020
Ekso Bionics Holdings, Inc.
(Exact Name of Registrant as specified in
its charter)
Nevada
|
|
001-37854
|
|
99-0367049
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
1414 Harbour Way South, Suite 1201
Richmond, California 94804
(Address of principal executive offices,
including zip code)
(510) 984-1761
(Registrant’s telephone number, including
area code)
Not Applicable
(Registrant’s former name or former
address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
|
EKSO
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02
|
Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On January 16,
2020, the board of directors of Ekso Bionics Holdings, Inc. (the “Company”) approved grants of equity awards to
Steven Sherman, a named executive officer of the Company, in respect of his continued service as the Company’s
Executive Chairman. These awards were made pursuant to the Company's Amended and Restated 2014 Stock Incentive Plan, and
consisted of options to purchase 250,000 shares of the Company’s common stock and 200,000 restricted stock units. The
option award becomes exercisable as to 31,250 shares on each of March 31, 2020 and the last day of each third month
thereafter. The restricted stock units vest as to 25,000 shares on each of March 31, 2020 and the last day of each third
month thereafter, and will settle upon Mr. Sherman’s separation of service from the Company.
All compensation for
the Company’s names executive officers for the fiscal year ended December 31, 2019 will be reported by the Company in the
Summary Compensation Table in the Company’s Annual Report on Form 10-K for the year ending December 31, 2019 or its proxy
statement relating to the Company’s next annual meeting of stockholders, to be filed with the Securities and Exchange Commission
no later than 120 days after December 31, 2019, or in an earlier report or proxy statement filed with the Securities and Exchange
Commission.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
EKSO BIONICS HOLDINGS, INC.
|
|
|
|
|
|
|
|
By:
|
|
/s/ John F. Glenn
|
|
|
Name:
|
John F. Glenn
|
|
Title:
|
Chief Financial Officer
|
Dated: January 22, 2020
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024